🔗 Share this article

An underground economy for unlicensed weight-loss drugs is propelled by social media fitness personalities and sellers on communication apps, according to new investigations.

Investigational Drug Gaining Traction Online

The experimental drug, which remains in clinical trials, is being promoted by social media influencers for its supposed weight-reducing effects. Followers are urged to contact these profiles directly for source information, while also receiving promotional offers.

Active Commerce on Messaging Platforms

Separately, a robust market exists on Telegram, where groups with thousands of members share comparison photos, administration instructions and assertions of rapid UK delivery. Vendors market the drug there before redirecting customers to other platforms for transactions.

Understanding Retatrutide

This medication is an investigational injectable created by American pharmaceutical company Eli Lilly. The drug targets three intestinal hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies indicate it could assist individuals reduce up to a quarter of their body weight. Nicknamed the “triple G”, the drug is being promoted online as the successor to Ozempic.

Healthcare Experts Voice Concerns

Nevertheless, physicians and pharmacists have cautions that the sale of what is still an unapproved medication in the UK is a cause for concern and could result in individuals injecting substances of uncertain source.

Some experts stated the demand for retatrutide could be linked to the increasing cost of approved weight loss treatments such as Mounjaro.

Regulatory Position and Enforcement

Selling the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unapproved medication that must not be marketed or supplied for human use under the Human Medicines Regulations 2012.

Several content creators try to circumvent the rules by calling to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a controlled substance, but promotion and supply can still violate medicines, advertising, and customer laws, risking fines, legal action or prison.

Service Reaction and Material Elimination

Based on TikTok, the platform has taken down violative content and prohibited related hashtags and query recommendations. The company said it was dedicated to maintaining the platform secure and allocating resources in strengthening enforcement strategies.

Online Marketplace Activities

Investigations also found groups with up to nine thousand participants marketing retatrutide using the platform's built-in discovery tool, which operates like a public directory. Typing “retatrutide” immediately displays groups with thousands of users, populated with photos of slimming results, positive testimonials and step-by-step instructions for preparing or administering at home.

After moments of entering one group, a vendor posted contact information, where most purchases take place. The vendor provided an guidebook and promised delivery within 48 hours. When questioned whether the product was authentic, one seller said: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. None inquired about weight, medical conditions or past usage.

Product Information and Costs

Inside these communities, messages show dark colored parcels with postal service stickers, claiming to include fresh supplies. One communication read: “It took eight of us to load them this morning.”

Buyers can choose between dry substance containers, prepared at home with purified liquid, or pre-filled injectors usually priced at £160 for 20 milligrams. When asked how long a pen should be used, vendors give conflicting responses varying between a several days to “depends on your body”.

Platform Moderation and Safety Actions

A spokesperson for the messaging service stated it regularly monitored harmful content on its platform including material that promoted the “misuse of controlled medications”. The company noted that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“People are administering materials they can’t verify. Although the research behind retatrutide is sound, these online versions may not include what they advertise,” stated a pharmacy expert, the director of pharmaceutical services at a pharmacy service.

A medical professional of an online medical service linked the surge in demand to recent cost increases for approved slimming medications such as Mounjaro. “With prices rising, patients are turning to online platforms. But fake treatments are highly dangerous. You can’t be certain what’s inside or whether the conditions they were produced in was sterile,” she said.

Her staff has previously seen individuals injured by personal administration from unconfirmed sources. “We understand the disappointment, but purchasing from Telegram or WhatsApp is taking chances with your well-being,” said the doctor. “These substances could be contaminated or incorrectly dosed.”

Manufacturer Position

A representative from the pharmaceutical company stated retatrutide was in third stage research studies and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Consequently at this point no one can sell [it] for personal consumption,” they explained, adding that any product “falsely representing itself as a company experimental product not yet approved … may expose patients to possibly serious health risks”.